A COMBINATION AND METHOD OF TREATMENT OF CANCER UTILIZING A COX-2 INHIBITOR AND A 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A (HMG-COA) REDUCTASE INHIBITOR

The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as "HMG-CoA inhibitor(s)") and a COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristics of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.
A COMBINATION AND METHOD OF TREATMENT OF CANCER UTILIZING A COX-2 INHIBITOR AND A 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A (HMG-CoA) REDUCTASE INHIBITOR

CONTINUATION DATA

For purposes of priority, including in the United States of America, this invention is a continuation-in-part of Provisional Applications 60/238,505 and 60/238506 filed October 6, 2000, Provisional Applications 60/243901 and 243,902 filed October 27, 2000, Provisional Application 245,592 filed November 17, 2000, Provisional Application 60/264,511 filed January 26, 2001, and Provisional application 60/307689 and Utility Application 09/912703 both filed on July 25, 2001 which provisional applications and utility application are incorporated by reference.

SUMMARY OF INVENTION:

The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as “HMG-CoA inhibitor(s)”), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer.

Methods of manufacturing are also claimed. The invention, however, is applicable to cancers generally in mammals and the reference to human biochemistry is not intended to be limiting, but illustrative. The term patient or body or reference to humans is utilized for convenience, but includes all mammalian patients or bodies.

Background:

Traditional cancer treatments have generally used an approach which is focused on directly attacking cells with a propensity to divide. The cancer cell is viewed as a bad cell that must be eliminated. The methods and combinations chosen focus on destruction of the dividing cell, or chemical attack of the cell.
This invention proposes a different methodology. The first premise is to recognize the highly adaptable characteristics and durable biochemistry of the cancer cell from a biochemical and genetic viewpoint. Many cancer cells are body cells gone awry. The literature solidly suggests that cancer cells in a patient’s body have a capability to readapt their functions to adjust to ambient conditions. A patient’s body also has an impressive capability to adapt to changing macro-environmental conditions, as well as the micro-environmental conditions in biological chemistry internal to the cell.

Cancer cells, in a genetic or evolutionary sense, are not “bad” cells. Rather, they are efficient cells; in fact, they are highly efficient cells in a certain way. They use relatively less oxygen for the total amount of activity they undertake, and they divide rapidly, enabling them by normal processes of mutation and evolution to adapt their genetic material more quickly. Were the systems and cells in the rest of our bodies equally efficient, we would be greater evolutionary giants than we stand today.

For any attack on cancer cells to be successful, unless they can be physically cut out of the body by surgery, the attack cannot be “too successful.” Cancer cells are us, and in a much slower evolutionary way, we are cancer cells. Too much success in damaging cancer cells pharmacologically in the prior art has often been destructive of the host body.

Returning to and illustrating the principle that the body is one large biochemical machine, suppose drops of salt water with colored salt are added to a larger volume of pure water in a container. The body is close to 98% seawater, meaning traditional H2O water with many other substances and compounds floating in the water. At first the drops would appear whole, but gradually the drops would dissipate so that the entire container might take on a tinge of color. The salt would be dispersed throughout the container so that, once equilibrium was established, all parts of the container had an equal concentration of the salt for each small volume of water. Before that equilibrium was established, the drops of colored water carrying the salt would tend to flow from areas of higher concentration (such as the original drops) to areas of lower concentration in the container (such as the “corners” of the container where there was originally no colored water. That tendency to flow from areas of greater concentration to lesser concentration calls for a resolution of osmotic imbalance generating a pressure gradient and is very
important to understanding this invention.

Our bodies are not however, a mere blob of water without structure. Cells are a packet of "sea water" with many compounds in the water surrounded by a membrane. Just like a pile of wet sand full of water will not hold its shape for building a sand castle, but is very strong and can form a formidable dike if the wet sand is in a bag, the contents of cells in a body, surrounded by a membrane, give the body of humans its structure. Metaphorically, human beings are a standing milieu of tiny piles of sea water in bags called membranes.

On a microscopic scale, the body acts the same way as the earlier described container of salt water. Drops in the form of minute or low concentrations of biologically significant chemicals gradually diffuse throughout our body through links from the membrane bags of sea water in systems of pipes called blood and lymph vessels. Taking advantage of differences in concentration, the blood vessels biochemically "transport" substances either to cells or from cells. Within cells, biochemicals travel by osmosis affected and influenced by biochemical cycles. When cells are short of glucose, the basic fuel product of food, cells have a lower concentration of a substance they need, and if there is a higher concentration of glucose in an adjacent capillary which has a blood cell, some of that glucose flows across the membrane in a complicated biochemical transport mechanism to restore the concentration of glucose in the cell, naturally depleting the concentration in the blood stream.

To complicate the picture in the body context, not all membranes allow all substances to pass. Some are only semi-permeable, allowing only compounds in certain shapes or sizes to pass. For those semi-permeable membranes, if the concentration of compounds on one side of the membrane changes, for instance, increases, then water will flow to that side of the membrane to re-balance the concentration.

Relying on the premise that cancer cells need to divide or replicate (since if they are stable they either pose less danger or are gradually eliminated), the invention takes advantage of that tendency of cancer cell's needs which cause chemicals to flow from areas of greater concentration to those of lesser concentration. First, cancer cells need energy in order to do what they do the most and best, which is to divide or replicate. Energy in a cell is provided by the Krebs cycle. Cancer cells, because they divide
frequently, are very sensitive to interference with their energy processes.

Second, when any cell divides, including cancer cells, the bag around the cell which is the membrane has to split into two bags. This presents two problems for the cancer cell. One, the cancer cell needs relatively more cholesterol in order to replicate successfully than a normal cell needs for its normal activities. Two, the membrane is necessarily weakened somewhat as the dividing process occurs and the cell transforms from one cell into two cells like a sandwich being pulled apart into two halves.

The human body is not completely helpless against cancers. However, cancer cells are relatively good at deceiving or confusing the immune system of our body into believing that the cancer cells are not as bad as they really are, or alternatively, because of rapid replication and evolution, developing defenses against the immune system. Further, as cancer progresses, it damages the body’s immune system, including by triggering long-term inflammatory mechanisms.

In total, this invention proposes to use a novel combination to inhibit key biochemical cycles in a way that causes more damage to the cancer cell than to other cells, to decrease long-term inflammation, and to improve and sustain the body’s immune system so it can better attack the weakened cancer cells and support the body’s remaining essential functions. The inventors propose to selectively modify several biochemical pathways so as not to destroy overall body function, but disproportionately harm cancer cells, to enhance the body’s immune system in order that the immune system may attack the cancer cells, and by stressing the cancer cell, to inhibit the cancer cell’s normal resistance to immune system function, and to protect the body’s normal cells.

The inventors propose a method of treatment of cancer, particularly prostate cancer and pancreatic cancer, by a particular combination of drugs for that purpose which has not been previously proposed for that purpose. The inventors propose a method of treatment of cancer involving a novel combination of drugs which simultaneously slows the cancer but also enables the body’s immune system to better attack or fend off the cancer.

The first object of this invention proposes to selectively interfere with the production of cholesterol in two places in a way that impairs the energy cycle of all cells but which normal cells can overcome because they need less energy to survive because
they are not dividing, but in a way that has a disproportionate and damaging effect on
cancer cells which must replicate, or the cancer will not spread. This object takes
advantage of the cancer cell’s requirement for cholesterol causing biochemical signaling
for cholesterol if not adequate to meet the replicating cancer cell’s needs.

A second object is to selectively modify a biochemical cycle that targets
inflammatory mechanisms in the body. One of the most damaging aspects of cancer cells
is that they trigger an extended inflammatory response in the body. Further, as cancer
progresses, it damages the body’s immune system by a number of mechanisms, including
the triggering of an extended inflammatory response in the body, which is less efficient in
the removal of cancers. Prostaglandins are some of the most important signals to cause
inflammatory responses. The biochemical cycle that we propose to selectively inhibit is
an important cycle that converts arachidonic acid to several forms of prostaglandins.
That cycle is the cyclooxygenase or COX cycle.

Biochemical cycles have many intermediate steps in them and the intermediate
compounds are known as “intermediates.” One of those intermediates in the
cyclooxygenase cycle is prostaglandin H2 synthase, which has two forms: COX-1 and
COX-2. COX-1 is known as a housekeeping substance which helps generate substances
that protect the stomach. Ding et al, “Blockade of Cyclooxygenase-2 Inhibits
Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells, vol. 20
AntiCancer Research, 2625-2632 (2000). Aspirin inhibits COX-1 and therefore, because
it inhibits a substance that protects the stomach, often has gastrointestinal side effects.
Recently, substances have become available that selectively inhibit COX-2 enzymes over
COX-1 enzymes. COX-2 enzymes regulate pain, inflammation and fever, i.e.
inflammatory mechanisms.

The COX-2 inhibitors in this invention interfere with the transformation of a
substance called squalene to cholesterol. There are numerous intermediates from
squalene to cholesterol.

Earlier in the biochemical cycle that produces cholesterol is a substance called
Acetyl-CoA enzyme. It is converted to an intermediate called mevalonate by an enzyme
called 3-hydroxy-3-methylglutamate-CoA reductase (“HMG-CoA”). Recent
pharmaceutical advances have produced a number of substances that inhibit the activity
of HMG-CoA and slow the production of cholesterol. HMG-CoA inhibitors have been used and are claimed to be used to reduce cholesterol to slow various blood vessel and related heart disease problems which we generally refer to as cardiovascular disease.

A third object of this invention is to utilize the more optimal function of cystine in the pH balance of a normal cell than in the lower pH of a cancer cell. The administration of cystine, enhances the body's immune system benefiting the total body disproportionately to any benefit cystine administration may have for a cancer cell.

In sum, the premise of this invention is that the cancer cells divide rapidly, that they have significant anaerobic glycolytic processes, and that the body is one large biochemical machine in which we can play to the strength of our body to the detriment of the cancer cell.

The science behind the combination is based on a triad of attacks on the biochemical pathways contributing to cancer cell replication.

Cancer cells must necessarily replicate for a "cancer" to thrive. Attacks on biochemical cycles at points where replication are involved are a favored approach.

Cancer cells are particularly vulnerable to interference with lipid cell membrane status and ATP synthesis.


Tumors and their malignant cancer cells multiply in an exponential growth pattern relative to other body cells. Any retardation of replication will have an exponential effect in slowing cancer growth. Any apoptosis of a cancer cell has a disproportionately exponential effect in retarding cancer. Current treatments such as chemotherapy and radiation therapy which have severe quality of life effects have relied on this disproportionately exponential effect to achieve what benefits those treatments do achieve for extending the life of patients.

This invention has the further benefit as distinct from prior art of accomplishing its benefits with substantially less interference with quality of life than chemotherapy and
radiation therapy(ies) in particular.

Discussion of certain specific patent and literature art:

One patent, Winokur, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled “Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease”, and a corresponding U.S. Patent 6,245,797, claims a combination of a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events and a method of using a COX-2 inhibitor with an HMG-CoA inhibitor for treating, preventing, and/or reducing the risk of atherosclerosis and atherosclerotic disease events. Another patent, Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled “Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions” proposes the utilization for an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor to treat, prevent or reduce the risk of acute coronary ischemic syndrome, thrombosis, and related vascular problems.

Certain literature has suggested that COX-2 inhibitors may have efficacy toward certain cancers. A review article sets out a good summary of COX-2 inhibitors. Fosslien “Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia,” Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502 (2000). In unrelated research, COX-2 inhibitors were reported to be inhibiting certain cancers, particularly familial adenomatous polyposis. See, 319 (7218) British Medical Journal 1155 (Oct. 30, 1999). COX-2 inhibitors, in that instance, celecoxib, a COX-2 inhibitor manufactured by G.D.Searle, and sold under the brand name Celebrex, had caused a reduction in adenomatous polyps which are a virtual guarantor of cancer of the colon if left untreated. Cyclooxygenase-2 had been implicated in colorectal cancer and colonic tumorigenesis. See, “The Relationship Between Cyclooxygenase-2 Expressions and Colorectal Cancer”, 282(13) J. Amer. Med. Ass’n:1254-1257 (Oct. 6, 1999).

Both celecoxib and rofecoxib are suggested to have similar effects. See, Vol. 56(2) Amer. J. of Health-System Pharmacy: 106-107 (Jan. 15, 1999). Unfortunately, like many (nonsteroidal anti-inflammatory drugs (NSAIDs), the COX-2 inhibitors are felt
to cause a range of gastrointestinal problems.

Based on the pharmaceutical product description of Merck for simvastatin, which
description is adopted herein and attached for reference, and which drug is marketed as
ZOCOR, a registered trademark of Merck, simvastatin functions in a similar way to
lovastatin, another drug marketed by Merck under the registered trademark of
MEVACOR, the pharmaceutical product description for which is adopted herein and
attached for reference. Both are derived from aspergillus terreus.

Certain literature has suggested that HMG-CoA inhibitors may have efficacy
toward certain cancers. Based on an article entitled, “Caspase-7 is Activated During
Lovastatin Induced Apoptosis of the Prostate Cancer Cell Line LNCaP” 58(1) Cancer
Research: 76-83 (1998), and a second article “Inhibition of the 3-hydroxy-
3methylglutaryl-coenzyme A reductase pathway Induces p53-independent
Transcriptional Regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells”,
prostate cancer. Patients to whom were administered lipid lowering/modifying drugs
such as lovastatin were suggested to be more cancer-free than those using bile acid-
binding resins. See, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and
the Risk of Cancer: A Nested Case-Control Study, 160(5) Archives of Internal Med:
2363-2368 (2000).

“Therapeutic Approaches to Bone Diseases [Bone Remodeling and Repair: Review],”
Science, 289(5484), Sept. 1, 2000:1508-1514.

No patent or literature suggests that the substances be combined to treat cancer
nor is the synergistic effect set forth in this specification suggested or described.

No patent or literature suggests the preferred embodiment that a COX-2 inhibitor
be combined with an HMG-CoA inhibitor to retard cancer and be further combined with
a glutathione-cycle enhancing compound such as cystine, cysteine, or N-acetyl-cysteine,
also called NAC, to improve immune system competency to further retard cancer.

No literature suggests another preferred embodiment: using a COX-2 inhibitor
and HMG-CoA inhibitor set forth in this invention to retard cancer.

Reduction to practice:
The combination of a selective COX-2 inhibitor and an HMG-CoA reductase
inhibitor exhibits the unexpected property of enabling management of cancer. This has been demonstrated in two specific instances. Both patients were diagnosed with Stage 4 metastatic cancer and were refractory to other treatments. The first patient had prostate cancer and showed a PSA (prostate specific antigen—a widely accepted marker of prostate cancer activity) of 71 according to the patient. The patient was placed on a regimen of VIOXX and MEVACOR, and has survived with good quality of life such as mowing his lawn, steady weight, and the like while the patient’s PSA fell from tests conducted by one of the inventors to less than 2.5 with scan-documented lack of progression. A second patient diagnosed with pancreatic cancer which was also refractory to other treatment was placed on a regimen of VIOXX and MEVACOR with a whey supplement containing cystine and survived approximately four months and initially gained some weight since first presenting while sustaining a reasonable quality of life until death. Pancreatic cancer is one of the most intractable cancers known and any success with pancreatic cancer is surprising in light of existing literature and art.

Pharmacological compounds in this invention:

The science behind the combination is based on a triad of attacks in the biochemical cycles contributing to cancer cell replication.

Cancer cells must necessarily replicate for a “cancer” to thrive. Attacks on biochemical cycles at points where replication are involved are a favored approach.

Cancer cells are particularly vulnerable to interference with lipid cell membrane status and ATP synthesis.

This invention proposes not only attack with a COX-2 inhibitor to interfere with the cyclooxygenase pathway, but by combination with an HMG-CoA reductase inhibitor, a statin, including simvastatin or lovastatin, focuses on another cycle, the formation of polyisoprenoids, particularly cholesterol.

The invention claims the use of selective COX-2 inhibitor, including rofecoxib or celecoxib, but the principles stated are generally applicable to all selective COX-2 inhibitors. The meaning and definition of Cyclooxygenase-2 inhibitor (“COX-2 inhibitor” or “selective COX-2 inhibitor”) in this invention shall include the following in this paragraph: all of the compounds and substances beginning on page 8 of Winokur WO99/20110 as members of three distinct structural classes of selective COX-2 inhibitor
compounds, and the compounds and substances which are selective COX-2 inhibitors in
Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled “Combination therapy for
treating, preventing, or reducing the risks associated with acute coronary ischemic
syndrome and related conditions”, and the compounds and substances which are selective
COX-2 inhibitors in Isakson et al, PCT application WO/09641645 published 27
December 1996, filed as PCT/US 9509905 on 12 June 1995, entitled “Combination of a
Cyclooxygenase-2 Inhibitor and a Leukotriene B4 Receptor Antagonist for the Treatment
of Inflammations.” The meaning of COX-2 inhibitor in this invention shall include the
compounds and substances referenced and incorporated into Winokur WO99/20110 by
reference to art therein, the compounds and substances referenced and incorporated into
Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, by reference to art therein, and the
compounds and substances which are COX-2 inhibitors referenced and incorporated into
Isakson et al, PCT application WO/09641645 published 27 December 1996, filed as
PCT/US 9509905 on 12 June 1995, entitled “Combination of a Cyclooxygenase-2
Inhibitor and a Leukotriene B4 Receptor Antagonist for the Treatment of Inflammations.”
The meaning of COX-2 inhibitor in this invention also includes rofecoxib, and celecoxib,
marketed as VIOXX and CELEBREX by Merck and Searle/Pfizer respectively.
Rofecoxib is discussed in Winokur, WO99/20110 as compound 3, on p.9. Celecoxib is
discussed as SC-58635 in the same reference, and in T. Penning, Synthesis and biological
evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification
of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-
2 inhibitor in this invention also includes SC299 referred to as a fluorescent
diaryloxazole. C. Lanzo et al, “Fluorescence quenching analysis of the association and
dissociation of a diarylhetercycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic
basis of cyclooxygenase-2 selectivity”, Biochemistry 2000 May 23 vol. 39(20):6228-34,
and in J. Talley et al, “4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2)”,
invention also includes valdecoxib, See, “4-[5-Methyl-3-phenyloxazol-1-
yl]benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2”, J.
Med. Chem. 2000, Vol. 43: 775-777, and parecoxib, sodium salt or parecoxib sodium,
0.5, or the second substituent should be an atom located on the periphery of the
compound selected from the group of a halogen F, Cl, Br or I, or A group VI element S
or O. Thus for purposes of this last included meaning of a COX-2 inhibitor, one portion
of the COX-2 inhibitor should be hydrophilic and the other portion lipophilic. Also
included as a COX-2 inhibitor are compounds listed at page 553 in Pharmacotherapy, 4th
nabumetone and entodolac. Recognizing that there is overlap among the selective COX-
2 inhibitors set out in this paragraph, the intent of the term COX-2 inhibitor is to
comprehensively include all selective COX-2 inhibitors, selective in the sense of
inhibiting COX-2 over COX-1. The package inserts for rofecoxib and celecoxib are
attached and adopted herein by reference. The inventors add to the class of COX-2
inhibitors useful in the invention the drug bearing the name etoricoxib referenced in the
Wall Street Journal, December 13, 2000 manufactured by Merck. See, also, Chauret et
al, “In vitro metabolism considerations, including activity testing of metabolites, in the
[5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(SH)-furanone]
referred in Yergey et al, Drug Metab. Dispos. 29(5):638-44 (May 2001). The
inventors also include as a selective COX-2 inhibitor flavolignanes which have selective
COX-2 inhibitory activity over COX-1 inhibitory activity, including the flavonoid
antioxidant silymarin itself, and an active ingredient in silymarin, silybinin, which
demonstrated significant COX-2 inhibition relative to COX-1 inhibition. The silymarin
also showed protection against depletion of glutathione peroxidase. Zhao et al,
“Significant Inhibition by the Flavonoid Antioxidant Silymarin against 12-O-
tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory
enzymes, and cyclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse
epidermis: implications in the prevention of stage I tumor promotion,” Mol. Carcinog.
Dec. 1999, Vol 26(4):321-33 PMID 10569809. Silymarin has been used to treat liver
diseases in Europe.

The term COX-2 inhibitor includes all pharmaceutically acceptable salts for the
selective COX-2 inhibiting compound selected. Examples of such salt forms of COX-2
inhibitors include but are not limited to salts derived from inorganic bases including
aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic
salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the
ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from
pharmacologically acceptable organic non-toxic bases include salts of primary, secondary,
and tertiary amines, substituted amines including naturally occurring substituted amines,
cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline,
N,N-dibenzyldihydrazine, diethylamide, 2-diethylaminoethanol, 2-
dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-
ethylpiperidine, glutamine, glucosamine, histidine, hydrazine, isopropylamine, lysine,
methylyglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine,
theobromine, triethylamine, trimethylamine, tripropylamine, troethamine, and the like.

The HMG-CoA reductase inhibitor claimed in this invention is lovastatin or
simvastatin or cholestin which are compounds related to aspergillus terreus. The
principles of this invention are generally applicable to all statins. The meaning and
definition of a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor ("HMG-
CoA inhibitor") in this invention is any selective, competitive inhibitor of HMG-CoA
reductase, the rate-limiting enzyme that converts HMG-CoA into mevalonate, generally
referred to as cholesterol-lowering statins, and includes
1) lovastatin, marketed under the trademark MEVACOR by Merck, and described,
among other places in U.S. Pat. 4,231,938,
2) simvastatin, marketed under the trademark ZOCOR by Merck, and described, among
other places in U.S. Pat. 4,444,784,
3) pravastatin, marketed under the trademark PRAVACOL by Bristol-Myers-Squibb, and
described, among other places, in U.S. Pat. 4,346,227,
4) atorvastatin calcium, marketed under the name LIPIITOR by Parke-Davis, and
described, among other places, in U.S. Pat. 5,273,995,
5) cerivastatin sodium, marketed under the name BAYCOL, by Bayer, and described,
among other places, in U.S. Pat. 5,177,080, and
6) fluvastatin sodium, marketed under the name LESCOL, by Novartis Pharmaceuticals,
and described, among other places, in U.S. Pat. 5,354,772.

The term HMG-CoA inhibitor (used as shorthand for and also referred to as “HMG-CoA reductase inhibitor”) further includes all HMG-CoA reductase inhibitors described in Winokur, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease,” and the compounds and substances which are HMG-CoA inhibitors in Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, entitled “Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions.” The meaning of HMG-CoA inhibitor in this invention shall include the compounds and substances referenced and incorporated into Winokur WO99/20110 by reference to art therein, and the compounds and substances referenced and incorporated into Nichtberger, U.S. Pat. 6,136,804, October 24, 2000, by reference to art therein. Compactin is also described as a fungi derived competitive inhibitor of HMG-CoA reductase. Lehninger, Principles of Biochemistry (3rd ed. 2000) at 811. An HMG-CoA reductase inhibitor, with the natural structure of lovastatin identical to the synthetic structure of lovastatin, can also be isolated from red rice yeast or the rice in sufficient quantity and is an HMG-CoA reductase inhibitor. The red rice yeast is found as cholestin or cholesterol and is available on the Internet from a variety places including China Beijing Jingxin Biochemical Products Factor, Linxiao Rd. S., Daxing Count, Beijing, PRC or its U.S. agent PHC Resources, Inc., 77 Milltown Rd., East Brunswick, NJ 08816. The red rice yeast is referred to in an FDA warning letter of May 8, 2001 to Maypro Industries available at www.fda.gov/foi/warning_letters/g1249d.pdf.

Based on the pharmaceutical product description of Merck for simvastatin, which description is adopted herein and attached for reference, and which drug is marketed as ZOCOR, a registered trademark of Merck, simvastatin functions in a similar way to lovastatin, another drug marketed by Merck under the registered trademark of MEVACOR, the pharmaceutical product description for which is adopted herein and attached for reference. Both are derived from aspergillus terreus.

Recognizing that there is overlap among the HMG-CoA inhibitors set out in this paragraph and in the list of six HMG-CoA inhibitors set forth above, the intent of the
term HMG-CoA inhibitor is to comprehensively include all HMG-CoA reductase inhibitors.

The term HMG-CoA inhibitor encompasses the pharmaceutically acceptable salts of HMG-CoA inhibitor selected. The invention includes pharmaceutically active salts of an HMG-CoA inhibitor, which may include non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base. Examples of salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, citrate, dihydrochloride, edentate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mutate, napsylate, mitrate, oleate, oxalate, pamaote, palpitate, panthothenate, phosphate/diphosphate, polygallacturonate, potassium, sodium, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate. The principles are also applicable to the inclusion of an additional ingredient, namely an edible resin that binds bile acids and prevents their reabsorption from the intestine, though this is not the preferred mode. Lehninger, Principles of Biochemistry (3rd ed. 2000) at 811.

Ester derivatives of the above described compounds included HMG-CoA inhibitors may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

The package inserts for COX-2 inhibitors and HMG-CoA inhibitors attached to the provisional application 60/245,592 and the description in the patents and methods in those patents related to the selective COX-2 inhibitors and HMG-CoA inhibitors are adopted by reference.

Cystine will be used as a generic reference for a glutathione pathway enhancing and detoxifying compound. Such compounds include the following:

Cystine is (3,3'-dithiobis [2-aminopropanoic acid]). Cystine is readily reduced to
cysteine. Cystine is present in most mammalian hair and keratin.
Cystine is 2-amino-3-mercaptopropanoic acid. It is readily converted by
oxireduction to cystine. It is a constituent of glutathione and abundantly present in the
metallothioneines.

Cystine in the body-useful form as L-cystine is available from Spectrum
Chemical Mfg. Corp. 14422 S. San Pedro St., Gardena, California 90248.
Cystine, cysteine, and N-Acetyl cysteine and pharmaceutically acceptable salts,
including the pharmaceutically active forms described in Kozhemyakin et al, published
by WIPO as WO 00/031120, PCT/RU99/00453, filed internationally on 19 Nov. 1999,
“Hexapeptide with the Stabilized Disulfide Bond and Derivatives Thereof Regulating
Metabolism, Proliferation, Differentiation and Apoptosis,” will all collectively be
referred to as cystine in this invention. Included in the term cystine is also any
therapeutically beneficial sulfur donating compound, including ebselen, which interacts
with the glutathione pathway. The invention contemplates in the term cystine
undenatured whey protein products designed to have enhanced cystine concentration as
well as protein products which contain cysteine and cystine. They can be in the form of
food products. Immunocal® whey protein diet supplement by Immunotek Research Ltd.
of Montreal Quebec is a useful product with cystine.

The addition of cystine, cysteine, N-acetyl cysteine, or the pharmaceutically
acceptable salt of those substances yields another effect in this invention not facially
evident from the independent properties of the basic components of the invention.
Administration of a glutathione pathway enhancing and detoxifying compound,
preferably cystine, which has the best and most rapid upload into the glutathione pathway
and better storage capability by the body, or N-acetyl cysteine, enhances the immune
system competency of the patient. Lipoic acid can be an adjunct to the cystine.

All of these cystine and cystine-like compounds function as a glutathione pathway
enhancing and detoxifying compound. They have the additional benefit of ameliorating
the negative renal, hepatic and gastric effects of COX-2 inhibitors and HMG-CoA
inhibitors, both as a combination and individually. The enhancement of the glutathione
level and pathway has a second important and unexpected effect. The avoidance of a
glutathione deficiency steers the patient to have a higher Th-1 response to Th-2 response
ratio than the patient would have with any glutathione deficiency

DESCRIPTION OF INVENTION:
The preferred mode of invention without limiting its use or use of pharmaceutical equivalents to those described herein is to administer a therapeutic dose of a cyclooxygenase-2 inhibitor, namely VIOXX (a registered trademark of Merck Co. for a drug formally known as rofecoxib) or CELEBREX (a registered trademark of Searle and Pfizer for a drug formally known as celecoxib) (both referred to as a “COX-2 inhibitor”), in combination with a therapeutic dose of a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor, namely with Mevacor (a registered trademark of Merck Co. for a drug formally known as lovastatin), or ZOCOR (a registered trademark of Merck Co. for a drug formally known as lovastatin) or cholestin (all referred to as “HMG-CoA inhibitor”) starting with the minimum initial recommended doses of each drug on the package inserts attached to provisional application 60/245,592. This mode is therefore a COX-2 inhibitor beginning with an HMG-CoA inhibitor in the minimum doses for each.

For patients who have advanced prostate cancer whose PSA does not respond to the combination, the dosage should be increased in step wise fashion to the maximum dose in the therapeutic window. The preferred mode of so doing is to monitor the patient each six weeks. A person of ordinary skill in the medical arts can apply the regimen described in this specification.

The inventors suggest measuring at least cholesterol level and isoprostane level. If a patient’s cholesterol level is decreasing, then the HMG CoA inhibitor is affecting cholesterol synthesis. If isoprostane levels are rising, then the COX-2 inhibitor should be having an effect. The lack of change in one or the other suggests that the medication to achieve the desired metabolic pathway effect should be adjusted.

Another way to test for effectiveness and enable dosage adjustment is to test cytokine levels. Once at least two inflammatory response markers show therapeutic change then the combination should be having an effect. The preferred markers include upregulation of IL-12 and downregulation of IL-10. “Specific inhibition of cyclooxygenase restores anti-tumor reactivity by altering balance of IL-10 and IL-12 synthesis”, J. Immunol 2000 vol 164(1) :361-370 [increased COX-2 expression increases
PGE-2 which induces IL-10; accordingly, use of COX-2 inhibitor leads to down-regulation of IL-10; also observed concomitant upregulation of IL-12. Testing of cytokines involves the use of ELISA assays to determine cytokine levels. Chemoluminescence tests are also used for certain interleukins. Other useful inflammatory response markers that may be tested include:

<table>
<thead>
<tr>
<th>Test/FactorName/range</th>
<th>Brief description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP C-reactive protein</td>
<td>General Inflammatory response marker, downregulation indicates amelioration of inflammatory response mechanism</td>
</tr>
<tr>
<td>IL-10 Interleukin-10 ED₅₀ =0.5 ng-1ng/mL</td>
<td>Potent blocker of activation of cytokine synthesis and sever accessory functions of macrophages; produced in CD4+ T cells and T cell clones, and other cells; downregulation indicates lessened interference with cytokine synthesis of cytokines needing upregulation and lessened macrophage activity interference</td>
</tr>
<tr>
<td>IL-2 Interleukin-2 0.0–4.0 pg/mL</td>
<td>Activates lymphocytes, potent stimulator of cytokine active killer cells (LAK’s) which demonstrate enhanced MHC non-restricted cytotoxicity. Used for renal cell CA-encouraging Tc1 activity</td>
</tr>
<tr>
<td>IL-6 Interleukin-6 0.0-149 pg/mL</td>
<td>Involved in T-cell activation; in nesting cells induce the expression of receptors for T-cell growth factor. Very important in inducing B-cells to differentiate into antibody-forming cells. In vivo stimulates production of acute phase proteins. Growth fac for multiple myeloma</td>
</tr>
<tr>
<td>IL-8 Interleukin-8 0.0-70 pg/mL</td>
<td>Proinflammatory cytokine released from range of cells incl monocytes, endothelial cells, epithelial cells, hepatocytes, fibroblasts and chondrocytes</td>
</tr>
<tr>
<td>IL-12 Interleukin-12 Range 0.7pg/mL-7000pg/mL</td>
<td>Potent initial stimulus for T-and Nk-cell, IFN(IFN=interferon production. May encourage Tc1 generation. Potentiates N to release IFN-8. Works in a manner complementary to II. increase in level compared to baseline indicates potential fe</td>
</tr>
<tr>
<td><strong>TNF</strong></td>
<td>Tumor Necrosis Factor</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------</td>
</tr>
<tr>
<td></td>
<td>0.0-4.9 pg/mL</td>
</tr>
<tr>
<td><strong>IFN-γ</strong></td>
<td>Interferon-gamma</td>
</tr>
<tr>
<td></td>
<td>0.0-1.5 pg/mL</td>
</tr>
<tr>
<td><strong>IFN-α</strong></td>
<td>Interferon-alpha</td>
</tr>
<tr>
<td></td>
<td>0.0-1.5 pg/mL</td>
</tr>
<tr>
<td><strong>ECP</strong></td>
<td>Eosinophilic cationic protein</td>
</tr>
<tr>
<td></td>
<td>1.5-5.5 mg/mL</td>
</tr>
<tr>
<td><strong>IL-10</strong></td>
<td>Interleukin-10</td>
</tr>
<tr>
<td></td>
<td>ED&lt;sub&gt;50&lt;/sub&gt; =0.5 ng-1 ng/mL</td>
</tr>
</tbody>
</table>

Advanced prostate cancer particularly refers to prostate cancer that has not been successfully treated by surgery, chemotherapy, radiation and/or androgen suppressant(s).

The same regimen is proposed for the commencement of treatment of other cancers.

The preferred mode of invention without limiting its use or use of pharmaceutical equivalents to those described herein is to use VIOXX (a registered trademark of Merck Co. for a drug formally known as rofecoxib) or CELEBREX (a registered trademark of Searle and Pfizer for a drug formally known as celecoxib) (both referred to as a “COX-2 inhibitor”), in combination with a therapeutic dose of a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor, namely with Mevacor (a registered trademark of Merck Co. for a drug formally known as lovastatin), or ZOCOR (a registered trademark of Merck Co. for a drug formally known as lovastatin) or cholestin (all referred to as
"HMG-CoA inhibitor") starting with the minimum recommended starting doses of each drug on the FDA package inserts attached to provisional application 60/245,592 for the treatment of prostate cancer, or the minimum therapeutically effective amount.

The invention retards or drives prostate cancer into remission, best illustrated by lowering the Prostate Specific Antigen, the standard measure of prostate cancer activity in the human body.

The method of the invention is the step of administering the combination of COX-2 inhibitor and HMG-CoA inhibitor, including lovastatin or simvastatin and rofecoxib or celecoxib, or the combined sequence of steps of sequentially administering the COX-2 inhibitor and HMG-CoA inhibitor, including lovastatin and rofecoxib. An alternative of this method of the invention is the combined sequence of steps of sequentially administering the COX-2 inhibitor and HMG-CoA inhibitor, including lovastatin or simvastatin and rofecoxib or celecoxib. Celecoxib may be used in lieu of rofecoxib, and simvastatin in lieu of lovastatin.

Another preferred method is the step of administering the combination of COX-2 inhibitor, HMG-CoA inhibitor, particularly lovastatin or simvastatin and rofecoxib or celecoxib, along with cystine as a glutathione pathway enhancing and detoxifying compound. An alternative of this method of the invention is the combined sequence of steps of sequentially administering the COX-2 inhibitor and HMG-CoA inhibitor, particularly including lovastatin or simvastatin, and rofecoxib or celecoxib, along with cystine as a glutathione pathway enhancing and detoxifying compound.

Also part of the invention is the method of manufacturing a combination of a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor, that is manufacturing a combination of an HMG-CoA inhibitor, including lovastatin or simvastatin, and a COX-2 inhibitor, including rofecoxib or celecoxib. Also part of the invention is the method of manufacturing a combination of a COX-2 inhibitor, a 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitor, namely manufacturing a combination of lovastatin or simvastatin, and rofecoxib or celecoxib, along with cystine as a glutathione pathway enhancing and detoxifying compound.

Thus, the prior discussion reviews one preferred mode of the invention, a COX-2 inhibitor and an HMG-CoA inhibitor. Another mode of the invention includes a COX-2
inhibitor and an HMG-CoA inhibitor, including rofecoxib or celecoxib and lovastatin or simvastatin and cystine or another glutathione pathway enhancing compound. As ATP and cholesterol synthesis is being affected in the cancer cell, cystine is being used to enhance the immune system competency and assist normal cells, through the glutathione pathway, in maintaining their stability.

The combination of a COX-2 inhibitor and an HMG-CoA inhibitor could also be used as an abortifacient.

The invention also can utilize one or more of certain additional active agents in combination with the HMG-CoA inhibitor and COX-2 inhibitor, or in combination with the HMG-CoA inhibitor, COX-2 inhibitor, and cystine. The additional active agents can be in a single dosage formulation, or may be administered to the patient in a separate dosage formulation, which allows for concurrent or sequential administration. Examples of additional active agents which may be employed include squalene epoxidase inhibitors, squalene synthase inhibitors, probucal, glycoprotein IIb/IIIa fibrinogen receptor antagonists, and pharmaceutically acceptable salts of those additional active agents which do not interfere with the HMG-CoA inhibitor and COX-2 inhibitor combination and method or with the HMG-CoA inhibitor, COX-2 inhibitor, and cystine. These and pharmaceutically equivalent agents in the same classes are described in the cited Winokur art, PCT Appl. US98/21901, filed 16 Oct. 1998, published as WO99/20110 entitled “Combination Therapy for Reducing the Risks Associated with Cardio and Cerebrovascular Disease” and in Nichtberger, U.S. Pat. No. 6, 136,804, Oct. 24, 2000. The therapeutically effective amount to use for these additional active agents is referred to in the just-cited art, can be seen in the Physician Desk Reference (PDR) 2001, and may be seen on the package inserts.

The instant pharmaceutical combination comprising an HMG-CoA inhibitor in combination with a COX-2 inhibitor and cystine includes administration of a single pharmaceutical dosage formulation which contains both the HMG-CoA inhibitor and the COX-2 inhibitor and cystine, as well as administration of each active agent in its own separate pharmaceutical dosage formulation. A cystine supplement taken at a different time of day may be a separate dose without the HMG-CoA inhibitor or the COX-2 inhibitor. Cystine is the suggested glutathione pathway enhancing and detoxifying
compound. The amount of cystine to be included in an oral dosage combination is a
therapeutically effective amount to reach normal glutathione levels. Such therapeutically
effective amount should preferably and initially be 140mg/70 Kg man twice per day.
Where separate dosage formulations are used, the HMG-CoA inhibitor and the
COX-2 inhibitor can be administered at essentially the same time, i.e., concurrently, or at
staggered intervals, i.e., sequentially. Without the cystine, the instant pharmaceutical
combination comprising an HMG-CoA inhibitor in combination with a COX-2 inhibitor
includes administration of a single pharmaceutical dosage formulation which contains
both the HMG-CoA inhibitor and the COX-2 inhibitor, as well as administration of each
active agent in its own separate pharmaceutical dosage formulation. The instant
pharmaceutical combinations are understood to include all these regimens.
Administration in these various ways is suitable for the present invention as long as the
beneficial pharmaceutical effect of the HMG-CoA inhibitor and the COX-2 inhibitor are
realized by the patient at substantially the same time. Such beneficial effect is preferably
achieved when the target blood level concentrations of each active drug are maintained at
substantially the same time. It is preferred that the HMG-CoA inhibitor and the COX-2
inhibitor be co-administered concurrently on a once-a-day dosing schedule; however,
varying dosing schedules, such as the HMG-CoA once per day and the COX-2 inhibitor
once, twice or more times per day, is also encompassed herein. In all courses of
administration, the therapeutic doses for cystine can be added, and likely necessitate an
additional therapeutic dose early in the administration regimen. As much as possible, a
single oral dosage formulation is preferred. A single dosage formulation will provide
convenience for the patient, which is an important consideration especially for patients
who may be in need of multiple medications. Administration of the HMG-CoA inhibitor
or COX-2 inhibitor can be by tablet, liquid suspension, or many other pharmaceutically
acceptable carriers known by or used by reasonably skilled practitioners in the art of
pharmacology or pharmaceutical manufacturing including by the combinations and
as WO99/20110 entitled “Combination Therapy for Reducing the Risks Associated with
Cardio and Cerebrovascular Disease” and in Nichtberger, U.S. Pat. No. 6, 136,804, Oct.
The active drugs can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. The active drugs may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. They may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propylmethacrylamide-phenol, polyhydroxy-ethyl-aspartamide-phenol, or polyethyleneoxide-polysilane substituted with palmitoyl residues. Furthermore, the active drugs may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepisolon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrazins, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. All of these are described in Nitchberger, U.S. Pat. 6,136,804, Oct. 24, 2000.

The term “therapeutically effective amount” is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. A therapeutic change is a change in a measured biochemical characteristic in a direction expected to alleviate the disease or condition being addressed. The term “prophylactically effective amount” is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. The term “therapeutic window” is intended to mean the range of dose between the minimal amount to achieve any therapeutic change, and the maximum amount which results in a response that is the response immediately before toxicity to the patient. The term “minimum recommended dose” is that amount either recommended in the package insert for the selected FDA approved drug, or for other substances and compounds, the minimum therapeutically effective amount for a typical patient of the size and weight being treated. Minimum recommended dose in the context of commencing treatment is also referred as
the minimum initial recommended dose and is that amount recommended for patients as
the starting dose. Adjustment of dose upward by 10% or "dose being adjusted upward by
at least 10% of the previous dose" means increasing the dose by that approximate
amount. In some instances the pharmaceutical carrier, or pill may have to be divided, but
generally an increase to the next highest dose is acceptable within the therapeutic
window. The references in the claims to specific dosages of specific FDA approved
drugs are to tablets having those dosages as referenced in the package inserts adopted

The dosage regimen utilizing an HMG-CoA inhibitor in combination with COX-2
inhibitor is selected in accordance with a variety of factors including type, species, age,
weight, sex and medical condition of the patient; the severity of the condition to be
treated; the route of administration; the cardiac, renal and hepatic function of the patient;
and the particular compound or salt or ester thereof employed. Dosages in all events
should be limited to the therapeutic window. Since two different active agents are being
used together in a combination therapy, the potency of each of the agents and the
interactive effects achieved by combining them together must also be taken into account.
A consideration of these factors is well within the purview of the ordinarily skilled
clinician for the purpose of determining the therapeutically effective or prophylactically
effective amount.

Discussion of pharmacokinetics and summary of literature:

The literature has suggested that an HMG-CoA reductase inhibitor may separately
have efficacy toward cancers, and that a selective COX-2 inhibitor may separately have
efficacy toward certain cancers, but no literature suggests that the substances be
combined to treat cancer.

In drawing conclusions concerning the pharmacokinetics, the inventors observe that
an intriguing and surprising aspect of the invention, which suggests many of the
pharmacokinetics, is that quality of life is not substantially affected by the treatment; the
patient is alive, the patient does not die; at the same time, at least in the short term, the
cancer is also present albeit repressed in its activity. The consideration of pharmacokinetics
attempts to comprehend these combined phenomena.

An important aspect of the pharmacokinetics is the selectivity to cancer cells and
essentially microadministration of cancer therapy. For instance, this invention proposes
to affect ubiquinones in important ways. There is art emerging, subsequent to provisional
application 60/263,486, to a pending trial of Ubiquinone under a trade name of Ubigel by
Gel-Tec, Drug Facts and Comparisons, 55th ed. 2001 at KU-16 (Publ. by Facts &
Comparisons 2000). Ubiquinone or CoQ-10 administration, in itself, is not likely have
the benefits of the present invention because it is proposed to be administered by
macroadministration to the entire organism, either orally or intravenously or in the
general vicinity of the tumor area.

By contrast to such effort at macroadministration, this invention proposes virtual
selective-to-cancer microadministration utilizing the body’s own metabolic mechanisms
and responses. This is a unique aspect of this invention and an important concept behind
the invention. The inventors propose that one of the dilemmas of cancer therapy is to
deriver the needed dose to the right place and minimize harm when the therapy is not in
the right place.

The inventors believe that the most optimal treatments involve the utilization of
the biochemical physiologic machine of the body, and preferably of the individual cell, to
construct, manufacture and adjust the individual cell chemistry to achieve the desired
object: in the case of the cancer cell or other afflicted and undesired cell, to disrupt its
mechanisms of replication, primarily by focusing on the energy mechanism of the cell
with the corollary result of interfering with membrane synthesis and cell replication, and
in many instances, as the cell struggles to reach homeostasis, inducing apoptosis.

In sum, by interfering with the cyclooxygenase pathway, particularly important in
the formation of prostaglandins, and thus in the cell-signaling mechanism critical for
replication of cancer cells, by directly interfering, using an HMG-CoA inhibitor, namely
lovastatin, with polyisoprenoid formation and disorienting the feedback regulation system
in that formation cycle, and later in that cycle, by utilizing a COX-2 inhibitor, preferably
rofecoxib, to further inhibit the formation of cholesterol, the invention renders cancer
cells vulnerable to poor replication and subject to bodily defenses, thus slowing the
cancer activity, and in the instance of prostate cancer, lowering the PSA of the patient
while destroying cancer cells.
The COX-2 inhibitor and the cyclooxygenase-prostaglandin pathway


Both celecoxib and rofecoxib are suggested to have similar effects. See Vol. 56(2) Amer. J. of Health-System Pharmacy: 106-107 (Jan. 15, 1999).

One of the clear benefits of the selective COX-2 inhibitor is that COX-1 isoenzymes have what has been characterized as having general housekeeping functions generally ameliorative to bodily health. Fosslien, "Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia," Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502 (November 2000). Aspirin, a classic COX inhibitor, also inhibits COX-1, thereby achieving anti-inflammatory effect, for which aspirin is well-known, at the cost of beneficial aspects of COX-1 isoenzymes. Thus, a COX-2 inhibitor that is selective is important in the invention.

A selective COX-2 inhibitor is important to this cancer management invention, but as the literature indicates, does not provide a comprehensive answer nor a comprehensive cancer response.
The COX-2 inhibitor and angiogenesis

In mice, a COX-2 inhibitor, NS398, was reported to inhibit angiogenesis of a prostate cancer specimen in vivo. Liu et al, “Inhibition of Cyclooxygenase-2 suppresses Angiogenesis and the Growth of Prostate Cancer in Vivo,” 164 J. of Urology 820-825 (September 2000) at 820.

Inhibition of cholesterol synthesis by COX-2 inhibitor and HMG-CoA inhibitor:

In viewing the biochemical cycle through which the formation of polyisoprenoids occurs, there are a series of intermediates. See, Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, published by Ciba-Geigy (1986) ISBN -0-91-4168-53-3, Lib. Cong. Cat. No. 81-70045 pp. 25-27, 142-147 (attached to Prov. Appl. 60/245,592, the text of which attachment is adopted by reference herein). A key end product of the biochemical cycle of formation of polyisoprenoids is cholesterol. In order for a cell to replicate successfully, the entire cholesterol cycle must be functioning properly and cholesterol is especially critical to membrane stabilization, a necessary ingredient for successful cancer cell replication.

The “early” cholesterol pathway: Acetyl CoA to mevalonate

Examining the intermediates in the polyisoprenoid formation cycle carefully, beginning with Acetyl-CoA, the next intermediate is 3-Hydroxy-3-methylglutaryl-CoA (“HMG-CoA”). There is a feed back regulation mechanism immediately after this intermediate before transition occurs to the next intermediate: Mevalonate. Salway, Metabolism at a Glance, 88-89 (Blackwell Science 2nd ed. Oxford 1999). The invention proposes to use lovastatin as an HMG-CoA reductase inhibitor. An HMG-CoA reductase inhibitor interferes in the polyisoprenoid formation cycle, and particularly interferes with cell wall synthesis, thereby interfering with a necessary construct of cancer replication. Because ATP cycle intermediaries are juxtaposed to the HMG-CoA feedback mechanism, and ATP and ATP cycle intermediaries are apparent in transition steps of biosynthesis of cholesterol subsequent to the Mevalonate intermediate, the effect of a cancer cell starved of necessary cholesterol is to biochemically invite increased production of intermediaries in the transition from mevalonate to cholesterol, and to biochemically invite increased production of HMG-CoA, whose biosynthesis is being inhibited. Such increased production draws on the ATP and ATP cycle intermediaries in
the cancer cell.

The later cycle: squalene to cholesterol synthesis

Continuing examination of the polyisoprenoid formation cycle, after the Mevalonate intermediate, the cycle continues with the formation of isopentenyl diphosphate, and then farnesyl diphosphate. Three intermediate products emerge after the farnesyl diphosphate intermediary: squalene, dolichols and ubiquinone. Salway, Metabolism at a Glance at 88-89, (Blackwell Science 2nd ed Oxford 1999).

A second effect cooperates with the HMG-CoA inhibitor to exacerbate the energy drain on a cancer cell. This collateral effect is additional to the effect of a COX-2 inhibitor on the cyclooxygenase cycle. While the HMG-CoA inhibitor has decreased the production of the subsequent intermediates to farnesyl pyrophosphate, the COX-2 inhibitor, because of the active electron field substituents, also interferes in a way not discussed in the literature with the normal biochemistry of squalene to cholesterol synthesis. Squalene transitions through a complex series of intermediates to cholesterol. This interference in the biosynthesis pathway subsequent to squalene synthesis further disables the cell division chemistry of a cancer cell and leaves it vulnerable to apoptosis. Notably, the transition states from squalene to cholesterol between intermediaries depend on critical inputs of ATP cycle chemicals, including NADP and NADPH. Salway, Metabolism at a Glance at 88-89, Blackwell Science 2d ed 1999). A COX-2 inhibitor interferes with, but does not appear to stop, synthesis of certain of these intermediaries. This either results in insufficient cholesterol for cancer cell replication or results in introduction of further drain on the ATP cycle chemicals to produce the desired cholesterol critical for cell replication. This drain on the ATP cycle is beyond the stresses already imposed by the HMG-CoA inhibitor. As the replicating cell has further need for cholesterol, further energy is diverted from the cell.

The “middle” of the cholesterol synthesis cycle: Farnesyl Pyrophosphate and ubiquinones

A corollary effect of the partial inhibition of the production of cholesterol from squalene and the triggering of increased production of farnesyl pyrophosphate is that relatively more ubiquinones are produced which are not being inhibited in the same manner as the squalene to cholesterol synthesis is inhibited.
Ubiquinones are key participants in the Q cycle in mitochondrial respiration. With the relative overproduction of ubiquinone that occurs in order to attempt to produce the requisite cholesterol for cell replication, one of two effects, or both effects, occur on mitochondrial respiration.

The replicating cancer cell either comes under osmotic pressure to decrease the concentration of ubiquinone, or the increased ubiquinone concentration changes the electron transport mechanism in the inner membrane of the mitochondria. If the cell admits fluid to stabilize the ubiquinone concentration, the cell must normally change size or shape to do so. Ellerby et al, Measurement of Cellular Oxidation, Reactive Oxygen Species, and Antioxidant Enzymes during Apoptosis, 322 Method in Enzym. 413 (Academic Press 2000), Bortner, Volume Regulation and Ion Transport during Apoptosis, 322 Method in Enzym. 421 (Academic Press 2000).

If the increased ubiquinone concentration changes the electron transport mechanism, the predicted effect is that there is a change in electron transfer from Complex 1 toward Complex 3. See Metabolism at a Glance, J.G. Salway, p. 12-15 (Blackwell Science Ltd., Oxford and London, 2nd ed. 1999).

Simultaneous to the ubiquinone effect, giving attention to both the COX-2 inhibitor with the hydrophilic and lipophilic substituents referred to earlier in this specification and the chemical potential of the unpaired electrons on the first and second substituents, the electrochemical potential and gradient between the matrix side of the membrane and the opposite side membrane is changed, which affects the proton pump and migration of H⁺ ions and in turn interferes with ATP synthesis. The likely reason is one of several, or a combination of several reasons. The COX-2 inhibitor, by changing the electrochemical gradient and potential across the membrane inhibits the potential need for ATP synthesis. Further, the electron attraction to the H⁺ cations on the matrix side, likely from the O=S=O bond in rofecoxib (or celecoxib), either slows the cation, potentially bonds and neutralizes them, or if an excess of electrons pushed by the ubiquinone shuttle from complex II to complex III encounters the cations, they potentially neutralize the H⁺ cations.

The cancer cell has an opportunity to again change the concentration to proper levels, but another osmotic pressure is generated. Any disruption in ion transport that
produces excess cytochrome would either be potentially fatal to the cell, or require yet another osmotic effect. Bortner suggests a volume loss or movement of ions is associated with cell apoptosis. “Cell volume is normally controlled within narrow limits.” Bortner, 322 Methods in Enzym. 422. Ellerby associates any change in cell size as either a coincident event to apoptosis or a precursor to completion of apoptosis phases. Ellerby, 322 Methods in Enzym. at 413-415. Bortner proposes the thesis that “When cells are placed in a hypertonic environment, shrinkage occurs because of the loss of osmotically obligated water. However, over a period of time diverse cell types compensate for the volume loss by activating a regulatory volume increase (RVI) response. This response allows for an influx of ions, with the concomitant movement of water into the cells to achieve a near-normal size.” Bortner, 322 Methods in Enzym. 422. Thus, there is movement of osmotically obligated water from the cell [or to the cell] to achieve a near normal cell size. If not successful, excess cytochrome has been implicated in the generation of caspases which often lead to cell apoptosis. Ellerby, 322 Methods in Enzym. 413-415.

Thus, the novel combination for retarding cancer does so in part by producing osmotic stress selectively in cancer cells, and in part by interfering with membrane synthesis in cancer cells. Movement of any osmotically obligated fluid has a corollary effect of also speeding into replicating cells potentially detrimental biochemicals from the body’s own immune system. Another corollary of any change in electrochemistry in the area of the matrix or the size of the cell is damage to ion transport channels, the blockage or overexpansion of which ion transport channel is often fatal to the cell. Ellerby, 322 Methods in Enzym. 413-421, Bortner, 322 Methods in Enzym. 421-433. The result of mitochondrial respiration uncoupling has been observed in conjunction with non-steroidal anti-inflammatory drugs. Fosslien, “Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia,” Crit. Rev. in Clin. Lab. Sci. 37(5): 431-502, pp. 453-455 (November 2000).

Since cancer replication is very sensitive to ATP cycle disruptions, the effect is to divert cell energy “unnecessarily” to attempting to overcome the effect of the HMG-CoA inhibitor and the COX-2 inhibitor and starve the cancer cell of necessary energy resulting in cytotoxic effect, apoptotic effect, or inhibition of replication.
Selectivity to cancer cells as a result of anaerobic function of cancer cells

The invention, either in the preferred mode of lovastatin and rofecoxib, or the alternative preferred mode of lovastatin, rofecoxib and cystine, takes advantage of the increased ratio of anaerobic to aerobic functionality of a cancer cell compared to that ratio in a normal cell. In the process of replication and mitosis, the growth rates of cancers parallel their level of differentiation and the relative number of their cells in mitosis. Mitoses are more abundant in the anaplastic rapidly dividing variants, meaning in the cancer cells that are creating “clones” of each other by cell division and replication. In most cancers that are associated with an increased number of mitoses and growth rate of cells, such proliferative activity results from the apparent loss of regulatory mechanisms apparent in normal cells. Cancer cells, without these regulatory mechanisms, are so engaged in the mitosis process with its significant energy demands, that both aerobic energy generation and anaerobic energy generation mechanisms are utilized. Nelson and Cox, Lehninger, Principles of Biochemistry (3rd ed. 2000) at 541.

In a normal cell, the combination of glutathione and internal cell biochemical controls enable an efficient disposition of cell wastes. In a cancer cell, the anaerobic processes of the cell to meet the cell’s energy demands result in use of glycolytic mechanisms even in the presence of what would be adequate oxygen supplies in a normal cell. The increased glycolytic processes, particularly the anaerobic processes, generate relative more waste product such as CO2 and lactic acid. Metabolism at a Glance, J.G. Salway, p. 32-33, 68-69 (Blackwell Science Ltd., Oxford and London, 2nd ed. 1999). Moreover, the COX-2 inhibitor shifts the reaction equilibrium to promote a higher concentration of arachidonic acid. Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, publ. by Ciba-Geigy (1986), p. 25-27; . Fosslien, “Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia,” Crit. Rev. in Clin. Lab. Sci. 37(5): 431, 433 (November 2000). Such relatively acidic environment in the cancer cell interferes with the functionality of the glutathione pathway which pathway is less efficient in an acidic environment.

Classic biochemistry indicates that the concentration of glutathione will fall in a more acidic environment such as the relatively more acidic cancer cell. Glutathione is gamma-Glu-Cys-Gly. The COO- ion on the end of the chain will be more present and a
more favored species in the less acidic environment of the normal cell.

The glutathione functionality is important in reducing reactive oxygen species to relieve subsequent oxidative stress which is deleterious to any cell. The effect in the cancer cell of the relatively reduced glutathione functionality and generation of increased wastes from increased and unregulated glycolysis is to either cause a slowing of the processes leading to waste production, thereby slowing replication, or to cause a change in osmolarity of the cell which is normally offset by increased water and a corresponding change in cell size. By contrast, in normal cells, an enhancement in relief of oxidative stress occurs, as well as maintenance of full functionality, thereby strengthening the immune system competency and total body system.

Another accomplishment of the invention not suggested by the literature is to utilize cystine to ameliorate the negative renal, hepatic and gastric effects of COX-2 inhibitors and HMG-CoA inhibitors, both as a combination and individually.

Unfortunately, like many non-steroidal anti-inflammatory (NSAIDs), the COX-2 inhibitors are felt to cause a range of gastrointestinal problems. This amelioration by the invention of negative renal, gastric and hepatic effects is accomplished by cystine, especially in a glutathione deficient patient.

The avoidance of a glutathione deficiency steers the patient to have a higher Th-1 response to Th-2 response ratio than the patient would have with any glutathione deficiency. Peterson, J. et al, “Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns,” Vol 95(6), Proceedings Nat'l Acad. Sci. USA p. 3071-76 (Mar. 17, 1998). This ameliorates negative gastrointestinal hepatic and renal effects. Another article, discussing 5-HETE and its association with prostate cancer, suggests that N-acetyl cysteine in the invention would not be efficacious. Miller et al., “5-HETE Congeners as Modulators of Cell Proliferation,” Bioorg. Med. Chem. Ltr. 10(17): 913-916 (Sep. 4, 2000).

The second and unexpected enhancement is independent of, but corollary to, the combination of the COX-2 inhibitor and HMG-CoA inhibitor. Though no source is cited, Fosslien suggests that antioxidants such as TROLOX also inhibit COX-2 induction: “Inhibitors of COX-2 induction are tumor suppressor protein p53, estrogen, and antioxidants such as Trolox (N-acetylcysteine, 6-hydroxy-2,5,7,8-tetramethylchroman-2-

The correlative effect is that the invention takes advantage of the very “strengths” of the vigorously metastasizing cancer whose strengths weaken the cancer cell’s response to cystine and the glutathione pathway because of the cancer cell’s Gompertzian growth characteristic.

*Lovastatin, its interaction with a selective COX-2 inhibitor and isoprostanes and the lipoxygenase pathway.*

The cited article entitled, “Caspase-7 is Activated During Lovastatin Induced Apoptosis of the Prostate Cancer Cell Line LNCaP” 58(1) Cancer Research: 76-83 (1998), and a second article, Lee et al, “Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway Induces p53-independent Transcriptional Regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells”, 273(17) J. Biol. Chem.:10628-23, (1998), reported that lovastatin had therapeutic value in treating prostate cancer. Patients to whom were administered lipid lowering/modifying drugs such as lovastatin were suggested to be more cancer-free than those using bile acid-binding resins. See, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study, 160(5) Archives of Internal Med: 2363-2368 (2000).

Lovastatin can be predicted to have another cooperative effect with rofecoxib with respect to cancer, especially prostate cancer. There is strong evidence that oxidative stress and subsequent free radical damage is very important in prostate cancer. Chung et al, Prostate Cancer: Biology, Genetics and the New Therapeutics, “Chemoprevention of Prostate Cancer” by Brooks and Nelson p. 365-375 at p. 369( Humana Press 2001).
**COX-2 inhibitor and the lipooxygenase pathway**

In examining the cyclooxygenase pathway, see Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemptner, publ by Ciba-Geigy (1986), p. 25, by application of Le Chatelier’s principle, an inhibition of the cyclooxygenase pathway will cause the concentration of arachidonic acid to increase. Such increased concentration will cause an increase in products produced in the lipooxygenase pathway. One of those products is Leukotriene B4. Leukotriene B4 is implicated in lipoperoxidative stress to cells.

**The lipooxygenase pathway and isoprostanes**

As a cancer cell signals for increased COX-2 expression which is being inhibited, the signal is directed to creation of further arachidonic acid (“AA”). The differentiation from normal cells is that a normal cell is not signaling for more AA to delivery more COX-2 expression. From both COX-2 inhibition and saturation from products of AA in the lipooxygenase (“LPO”) pathway, a significant buildup of AA occurs which can be most easily relieved from a redox viewpoint by creation of isoprostanes.

Such excess production has implications for the lipooxygenase metabolic pathway. The evidence for this lipooxygenase pathway effect is seen in isoprostanes which are prostaglandin-like compounds which are formed by free radical catalysed peroxidation of arachidonic acid esterified in membrane phospholipids (Neurochem Res 2000 Oct;25(9-10):1357-64).

Unfortunately for the cancer cell, isoprostanes are indicators of damage to membrane phospholipids. Arachidonic acid (AA) is esterified in the membrane phospholipids, and when oxidized, isoprostanes are the end-product. The peroxidation products are monitored by measuring the isoprostanes and lipid peroxides. For a rapidly dividing cancer cell in which membrane synthesis is critical, the increase in arachidonic acid and its potential damage to membrane phospholipids has negative implications for replication success. The rise in isoprostane levels shows that oxidation of excess arachidonic acid is occurring. This is one mechanism for the damage from excess arachidonic acid that may be seen with the use of the COX-2 inhibitors and contributes to explaining the toxic effect of a COX-2 inhibitor, especially in rapidly dividing cells. However, presence of the isoprostane in the blood or urine would signal an upper limit has been reached of the COX-2 inhibitor above which the risk of kidney or liver damage may increase.
Lipid peroxidation is best characterized as a series of chain breaking reactions in
the lipid bi-layer at the membrane which inhibits the proper growth of proteins. The
membrane is rendered more porous and susceptible to degeneration, or to penetration by
other molecules in the body’s immune system. Analogously, lipid peroxidation by heat
occurs in an egg white when heated. In the body, and as is desired in cancer cells, such
lipid peroxidation occurs chemically.

The HMG-CoA reductase inhibitor simvastatin has been shown to produce
positive effects in the endothelial lining of blood vessels even independent of its lipid
lowering effects. Animals with high cholesterol diets who exhibited continued high
serum cholesterol who were administered simvastatin demonstrated a lower rate of
production of F(2)-isoprostanes and thiobarbituric acid-reactive substances (TBARS),
markers of oxidative stress, than animals who were not treated with simvastatin and
maintained on a high cholesterol diet. Arterioscler Thromb Vasc Biol 2001
Jan;21(1):122-8). Simvastatin is an analog of lovastatin, which are both statins produced
from aspergillus terreus.

The presence of the HMG-CoA reductase inhibitor may contribute to moderating
the effects of lipid peroxidation produced in the normal cells moderating production of
isoprostanes.

While a protective effective may not seem facially desirable, consideration needs
to be made of the selectivity which occurs. The cancer cell metabolic pathways which
result in the higher expression of COX-2 in cancer cells, which the invention proposes to
inhibit, suggest that cancer cells utilize COX-2 in a meaningful way, a conclusion
supported by the apparent partial efficacy of COX-2 inhibitors against cancer. In order to
obtain COX-2, cancer cells have a signaling system to stimulate the precursor of COX-2,
which is arachidonic acid. Normal cells which do not have a similar need for COX-2
apparently do not have such a signaling system.

For a cancer cell which under normal replication conditions will experience a
more rapid genesis of lipid peroxidation products from membrane synthesis, the inventors
surmise that the partial protective effect of a statin to slow the rise in isoprostane levels is
selectively insufficient to protect the cancer cell from excess arachidonic acid, while
acting protectively in normal cells. As a corollary, whatever offsetting benefit the statin
may have against the lipoxygenase pathway products is not sufficient to overcome either
the toxic effects of excess arachidonic acid, nor to offset the cholesterol synthesis
inhibition occurring in the cholesterol synthesis pathway with respect to production of
mevalonate and occurring with respect to excess geraniol as a result of interference with
squalene conversion to cholesterol.

Thus, there is a selective effect of increased toxic metabolites when a COX-2
inhibitor is administered as evidenced by increased isoprostane levels, with end products
that have primary toxicity to cancer cells from excess lipid peroxidation and the LTB4.
Biochemistry, Geigy Scientific Tables, Book 4, ed. by C. Lemtner, publ by Ciba-Geigy

Testing of isoprostanes and TBAR's can be used to determine if excessive
amounts of lovastatin or any statin are being used and as an indicator of the level of
lipoxygenase peroxidation effects.

Another product that can result from increased arachidonic acid is 5-HETE which
has been implicated in prostate cancer. Miller et al, “5-HETE Congeners as Modulators
of Cell Proliferation,” Bioorg. Med. Chem. Ltr. 10(17): 913-916 (Sep. 4, 2000). It is
poorly disposed of. However once saturated, it will cause increased arachidonic acid
buildup if arachidonic acid buildup is being artificially stimulated such as by a COX-2
inhibitor. Further evidence of this effect of increased AA concentration is shown
from experiments with γ-linoleic acid which is the precursor of arachidonic acid through
the formation of dihomo-γ-linoleic acid (“Metabolism at a Glance”, Salway, 2nd edition,
BlackWell Sciences, UK pg. 86). Conjugated linoleic acid (CLA) is prone to oxidation,
and it has been suggested that increased oxidation of lipids may contribute to an anti-
tumorigenic effects of this agent. Clin Sci (Colch) 2000 Dec;99(6):511-6. There,
researchers followed levels of 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)), a
major isoprostane, and of 15-oxo-dihydro-PGF(2alpha), a major metabolite of
PGF(2alpha), (collectively referred to as isoprostanes) and tested their levels, as
indicators of non-enzymic and enzymic arachidonic acid oxidation respectively after
dietary supplementation with CLA in middle-aged men (mean age 53 years) with
abdominal obesity for 1 month in a randomized controlled trial. Thus, the addition of
CLA to the diet of people undergoing metabolic cancer therapy with a Hmg-CoA and a
COX-2 inhibitor would result in an enhanced effect by increasing the lipid oxidation
effect of the isoprostanes, and shows the creation of excess arachidonic acid has
antitumorigenic effect as predicted by the inventors.

Using the isoprostane levels as indicators, the treatment dose of the COX-2
inhibitor can be maximized to give the maximum tolerated dose for use in cancer therapy
without creating excessive systemic toxicity. More lipid oxidation activity indicates
increased oxidative stress, usually a characteristic of cancer activity. A long-term falling
level of isoprostanes will mean for COX-2 expressing cancers that there is relatively less
cancer risk. An ELISA test for isoprostane level is available from Cayman Chemical

For a membrane-impaired cancer cell, receptors and transport molecules for
materials needed for cell survival tend to be overloaded and the cell does not function
properly, much less have much chance of replicating accurately with an intact membrane.
Additionally, in this invention, the shift in concentration caused by excess ubiquinones
toward semiquinone triggers increased lipid peroxidation. Nohl, “Antioxidant-derived
1998). While the statin can ameliorate the tendency to lipid peroxidation, which is why a
lower dose is preferred, it need only be sufficient to impair cholesterol synthesis, and
there remain sufficient lipid peroxidants to damage cancer cells while normal cells are
slightly protected.

The presence of ubiquinones in normal cells with adequate glutathione does not
materially change their characteristics; however in cancer cells, the excess ubiquinones
in combination with the already nascent tendency to express lipid peroxidation
sufficiently the weakens the cells to expose them to immune system attack, a tendency
not overcome by the presence of glutathione which is less active in the more anaerobic
environment of a cancer cell.

*Lovastatin and its inhibition of farnesyl pyrophosphate and
geranylgeranylpyrophosphate*

Lovastatin has another inhibitory effect which has implications for both
cholesterol synthesis, ubiquinone concentration, and farnesyl pyrophosphate
concentration. “Lovastatin, an HMG-CoA reductase inhibitor that inhibits the
biosynthesis of farnesylpyrophosphate (PPP) and geranylgeranylpyrophosphate (GPP), is
used routinely as a positive control for inhibition of processing of both
geranylgeranylated and farnesylated proteins [citations omitted].” A. Vogt et al, “A Non-
peptide Mimetic of Ras-CAAX: Selective inhibition of Farnesyl Transferase and Ras
Processing,” 270(2) J. Biol. Chem. 660-664 (2000). In addition to additional direct
cholesterol inhibition, Salway, Metabolism at a Glance at 88-89 (Blackwell Science 2nd
ed. 1999), the effect of any FPP inhibition is to directly inhibit production of dolichols,
which has implications for dolichol phosphate which affects messenger RNA
transcription. Since cancer cells are attempting to replicate, a selective effect on cancer
cells by affecting messenger RNA is achieved. Lehninger on Biochemistry at 1059, 3rd
ed. GPP inhibition likely has the same effect as post-lanosterol cholesterol cycle
inhibition in that additional energy must be used to overcome inhibitory effects. The
Vogt article also notes that cysteine is important in ras oncogene activation. This teaches
away from the benefits of glutathione pathway protection, but the inventors suggest that
the combination of diversion of glutathione pathway resources to stabilize other
adversely affected metabolic pathways of a cancer cell is likely sufficient in combination
with FPP and GPP inhibition to interfere with cell replication. What FPP is generated
will be diverted to enhance cholesterol synthesis making it less available for ras oncogene
activation in conjunction with cysteine.

Lipid peroxidation and reactive oxygen and nitrogen species

The article entitled “Reactive Oxygen and Nitrogen Species: Efficient, Selective,
and Interactive Signals During Intercellular Induction of Apoptosis; Georg Bauer,
Abteilung Virologie, Institute for Medizinische Mikrobiologie und Hygiene, Universität
Freiburg, D-79104 Freiburg, Germany; Anticancer Research 20: 4115-4140 (2000)
contains a comprehensive discussion of the interplay of reactive nitrogen species and
oxygen species with apoptosis. See also, Bolanos, Nitric Oxide, Mitochondrial Function
Bauer article sets out a series of chemical equations related to processing of reactive
oxygen and nitrogen species.

The issue is what about a selective COX-2 inhibitor, the overproduction of
ubiquinones, and the interference with mitochondrial respiration, assuming an adequate
supply of glutathione, enables the invention to be effective. We have already recognized
that additional energy will be needed to generate cholesterol both because of HMGCoA
inhibition and squalene-to-cholesterol synthesis inhibition.

The answer from the Bauer article focuses on the tendency of excess NO and OH
species, particularly in their free radical forms, to accelerate lipid degeneration.

As stated previously, lipid peroxidation is best characterized as a series of chain
breaking reactions in the lipid bi-layer at the membrane which inhibits the proper growth
of proteins. The membrane is rendered more porous and susceptible to degeneration, or
to penetration by other molecules in the body’s immune system.

In an article entitled “Antioxidant-Derived Prooxidant Formation from
that “Our studies on the antioxidant activity of ubiquinol in peroxidizing lipid membranes
demonstrate the existence of ubisemiquinone (SQ•) as the first reaction product of
ubiquinol. A reaction of SQ• derived from the localization allows an access of protons
and water from the aqueous phase to SQ• [•] a prerequisite earlier found to trigger
autoxidation. Superoxide radicals emerging from this fraction of autoxidizing SQ• form
H₂O₂ by spontaneous dismutation. SQ• not involved in autoxidation may react with
H₂O₂. Transfer of the odd electron to H₂O₂ resulted in HO• and HO- formation by
homolytic cleavage. An analogous reaction was also possible with lipid hydroperoxides
which accumulate in biological membranes during lipid peroxidation. The reaction
products emerging from this reaction were alkoxyl radicals. Both HO• and alkoxyl
radicals are strong initiators and promoters of lipid peroxidation.” Id. Abstract to
“Antioxidant-Derived Prooxidant Formation from Ubiquinol...,” Nohl et al, Free Radical

To summarize the important postulates of Bauer with respect to their
interrelationship with this invention, first, •NO in the presence of O₂•- forms
peroxynitrile ONNO-. This is not stable. Interestingly, this peroxynitrite is not a free
radical. However, in the acidic environment of a cancer cell, there is a propensity to form
the instable peroxynitrous acid.... Peroxynitrile has the potential for lipid peroxidation
(no formula shown [in the article]). Id. at 4119. “Singlet oxygen, formed after
interaction of hydrogen peroxide and peroxynitrite [f.n. omitted] has an extremely short half-life and has the potential for lipid peroxidation [f.n. omitted]. Nitric oxide, though being a free radical shows a long range of action and rather low toxicity. It inhibits lipid peroxidation and caspases. Interaction of nitric oxide with superoxide anions causes the formation of peroxynitrite, a potent lipid peroxidant and apoptosis inducer.” Id. at 4116. There are a series of reactions, several of which involve glutathione.

The positive empirical results from the patients on which this invention was tested indicate that peroxynitrite acts as a strong oxidant when increased there is cytokine production. With the increase in ubiquinones causing increased production of superoxide, relatively more of which is available in cancer cells to cause peroxynitrite formation at appropriate pH, the peroxynitrite can cause direct damage to proteins. The second and third reactions discussed are degeneration by homolysis, •OH- + •NO2, or heterolysis degenerating to •OH- + NO+. Even the fourth reaction, ONOOH to ONOOH+ is troublesome for a cancer cell because of the creation of a more acidic environment.

Equally apparent from the equations is the importance of glutathione in detoxification of radical species and prooxidant species such as ONNO-. Glutathione is thought to have a protective effect in a number of instances. However, as postulated, glutathione functions more actively in an anaerobic environment. As a cancer cell’s energy needs are stressed by a COX-2 inhibitor, more anaerobic respiration occurs, lowering the pH of the cancer cell slightly, shifting even glutathione reactions away from oxidation to more benign species and generating more free radical damage and accelerating lipid peroxidation. While cancer cells having complete angiogenesis will be less affected by these reactions, the inclination to apoptosis and the degeneration of angiogenic species either as a result of the death of a cell, or the waste of energy in the tumor to generate unutilized angiogenesis both inhibit the cancer cell’s growth. Bauer notes that his key reactions occur early in tumor development prior to angiogenesis, Bauer, 20 AntiCancer Research at 4115, a result consistent with the inventors’ clinical observation that cancer is not eliminated but retarded or managed by the invention.

The presence of ubiquinones in normal cells with adequate glutathione does not materially change their characteristics; however, in cancer cells, the excess ubiquinones
in combination with the already nascent tendency to express lipid peroxidation
sufficiently weakens the cells to expose them to immune system attack, a tendency not
overcome by the presence of glutathione which is less active in the more anaerobic and
more acidic environment of a cancer cell.

Metal complex ions and glutathione

Another aspect to consider is that H$_2$O$_2$ has a potential rescuing effect for cells to
blunt NO mediated apoptosis at high cell density. A primary generator of H$_2$O$_2$ is
 glutathione reactions which in a normal cell environment remove hydroxyl radicals, and
 nitric oxide radicals. In conjunction with metal ions, particularly copper, zinc and
 magnesium, in glutathione competent cells, the H$_2$O$_2$ breaks down into water. As
explained by Bauer, cells are in a sense rescued from apoptosis in that situation. In cells
not so equipped, which would include a number of cancer cells in a tumor, more
hydroxyl radicals are generated, and there is not a rescue from apoptosis. The fact that,
as explained by Bauer, H$_2$O$_2$ is a far-ranging species that can intercept NO species far
from a cell membrane may explain for small cell cancers, where intercellular range is less
of an issue, the relatively toxicity and tumorigenicity of those cancers where the range of
operation is less of a factor in what self-protective mechanisms the body has to battle the
cancer. The presence of HOCl cannot be ignored which Bauer believes interacts with
H$_2$O$_2$ to generate non reactive molecules such as oxygen, water, chloride anions and

Notably, however, Bauer remarks that the speed of reaction is not significant
unless reaction number 3 [HOCl +H$_2$O$_2$ to O$_2$ +H$_2$O+Cl$^{-}$ +H$^+$] is blocked by SOD
which is more likely to occur in the COX-2 inhibitor affected cancer cell because of the
shift in electron concentration generating more potential O$_2$-. Bauer, 20 AntiCancer
Research 4118-19. As the kinetics for this reaction to occur become more favorable,
SOD, which has been stably attached to Mn, Zn or Cu, is detached as the reaction
proceeds and the SOD performs its catalytic function. The resultant free radical metal
ion generated, in the presence of HOCl, accelerates lipid peroxidation. Bauer, Anticancer

Glutathione (GSH), a critical element in immune system function, unquestionably
has some positive effects for the cancer cell because it can scavenge free radicals. Yet
this is needed in all cells. Glutathione does have a favorable effect on cancer cells through its protection of the disulfide bridges. Protection of disulfide bridges inhibits lipid peroxidation therefore protecting protein structure, particularly tertiary and quaternary structures. "Glutathione probably helps maintain the sulphhydryl groups of proteins in the reduced state and the iron of heme in the ferrous (Fe2+) state, and it serves as a reducing agent for glutaredoxin in deoxyribonucleotide synthesis (see Fig. 2-37 [in source]). Its redox function is also used to remove toxic peroxides formed in the normal course of growth and metabolism under aerobic conditions: 2GSH + R-O-O-H to GSSG + H2O + R-OH." Lehninger, Principles of Biochemistry (3rd ed. 2000) at 842. As is apparent from the quotation, any effect on glutathione supply, such as failure to remove toxic peroxides, or lack of presence for deoxyribonucleotide synthesis because of competitive consumption to maintain homeostasis in cancer cells has serious implications for cell division and replication, which is the lifeblood and toxicity of cancer.

Glutathione, however, will be slightly less present in the acidic environments of cancer cells. Glutathione is gamma-Glu-Cys-Gly. The COO- ion on the end of the chain will be more present and a more favored species in a less acidic environment. The more acidic environment of anaerobic glycolysis in cancer cells causes a shift to moderately lower relative glutathione concentrations, and consequently less protection from apoptotic free radical reactions.

The implications of metal ion reactions and glutathione, as seen in the Bauer equations, Anticancer Research 20: 4118-19 (2000), are that glutathione absorption in stabilizing free radicals to convert them to H2O2 has implications in coincidentally affecting the reaction kinetics of superoxide dismutase (SOD) and affecting the metal ion chemical reactions illustrated by Bauer under "M" at Anticancer Research 20: 4118.

This invention does not propose to be prima facie a cancer cure, but rather a prima facie cancer manager. The competitive consumption of energy to overcome cholesterol synthesis, to overcome interference with mitochondrial respiration, and the competitive consumption of GSH to thwart lipid peroxidation, and to rescue cancer cells from reactive oxygen and nitrogen species either weakens existing cells, weakens newly generated cells (which may then undergo self-apoptosis) or inhibits membrane and DNA synthesis or all of these. The inherent characteristics of replicating cancer cells and the
necessary anaerobic enhancement to their energy processes enable the invention to
selectively attack cancer cells while normal cells and their homeostatic processes can
protect the mammalian organism which the inventors desire to preserve. Moreover, the
administration of the compounds in the invention enable the organism to achieve the
senescence which cancer cells have attempted to elude through a variety of mechanisms
that the body in many instances is helpless to resist. The use of HOCl, and the
application of NO•- and OH•- is the usual means to achieve senescence, and the
invention enables proper operation of that mechanism.

NADPH concentration, COX-2 inhibitors and apoptosis

A corollary effect of the inhibition of creation of cholesterol relates to the shifting
of equilibrium toward to squalene and a higher concentration of NADPH+H+ as a result
of the action of the COX-2 inhibitor. As remarked by Bauer, what is at issue is high
speed bursts of adjacent NO/O2- activity which can damage membranes and cells. The
marginal and momentary increase in NADPH +H+ has a series of contradictory effects.
Exterior to the mitochondria, increased levels of NADPH can be seen to slow reactions
in the pentose phosphate pathway, namely in the transition from glucose 6-phosphate to
ribulose 5-phosphate. Selective shifts in this pathway affect glucose-6-phosphate, though
perhaps only mildly. NADPH concentration shifts also slow the conversion of malate to
pyruvate, a precursor to acetyl CoA, a precursor to cholesterol, a possible positive in
inhibiting cancer cell membrane synthesis. Another effect is a buildup of lactic acid with
concomitant cytotoxic effects for cells unable to tolerate increased acidity. Salway, Id. at
pp. 49, 60. Salway remarks on this shift indirectly, noting that “during re-feeding after
fasting, glucose is metabolized anaerobically to lactate by muscle even though the
conditions are aerobic. This is because, immediately after refeeding, the high ratio of
acetyl CoA to pyruvate caused the lingering B-oxidation of fatty acids, results in pyruvate
dehydrogenase remaining inhibited... Consequently, glucose in muscle is metabolized to
pyruvate which is reduced to lactate. Salway, Metabolism at a Glance (Blackwell
Science Oxford 1999) at p. 60. A similar effect occurs occurs for cancer cells affected
by an HMG-CoA reductase inhibitor. The increased acetyl CoA buildup in cancer cells
causes increased lactate production. Salway, Id. at 51. That lactate tends to slightly
acidify the cancer cell, which has implications in induction of apoptosis. In normal cells,
homeostasis is such that an Acetyl CoA imbalance is not toxic on refeeding after
starvation because the Acetyl CoA/CoA precursor ratio is not affected.
In cancer cells where increased Acetyl CoA has to be present to overcome the
inhibition of synthesis of cholesterol, there is a transient increase of acidity, favoring the
reaction of peroxynitrite to NO- and OH- apoptotic free radicals.
NADPH is also implicated in the presence of NADPH oxidase in the generation
of free electrons leading to O2•- species. As explained by Bauer, these are implicated in
induction of apoptosis. In cancer cells demanding cholesterol, as the reactions of
intermediates from squalene and lanosterol to cholesterol are slowed by a selective COX-2 inhibitor, there are momentary increases in NADPH. This has apoptotic effects
selective to cancer cells as opposed to normal cells.
The discussion above, and the article by Bauer, "Reactive Oxygen and Nitrogen
Species: Efficient, Selective, and Interactive Signals During Intercellular Induction of
Apoptosis," *Anticancer Research* 20: 4115-4140 (2000), amply confirm and correlate
with the observations of Ellerby et al, Measurement of Cellular Oxidation, Reactive
Oxygen Species, and Antioxidant Enzymes during Apoptosis, 322 Method in Enzym.
413 (Academic Press 2000), Bortner, Volume Regulation and Ion Transport during
Apoptosis, 322 Method in Enzym. 421 (Academic Press 2000) regarding the apoptotic
cascade that can be triggered by the osmotic pressures on a cancer cell as it struggles to
maintain chemical homeostasis. The chemical kinetics and reactions confirm the clinical
observations with respect to the invention. On balance, the tendency of the combinations
in the invention is to selectively disfavor cancer cells based on the inventor’s empirical
observations. The inventors also note that the explanation of pharmokinetics is consistent
with the tendency of tumors, once expanded to have a mass of necrotic tissue within them
(another complicating factor of cancer), suggesting that glutathione activity,
accumulation of wastes and apoptosis are natural mechanisms of cancer cells which the
science of this invention attempts to exploit at an earlier stage of cancer cell development
in order to manage tumor activity.
*Metal complex interactions:*
The interaction of nitrous oxide and reactive oxygen species is one of the most
important apoptotic triggers in anti-tumor activity. As previously discussed, COX-2 has
two interactions with mitochondrial respiration and ATP utilization, one direct and one indirect. The direct interaction is the lipophilic/hydrophilic orientation which can inhibit the F0/F1 channel in complex IV. Salway, Metabolism at a Glance at 14-15 (Blackwell Science 2nd ed. 1999). The indirect interaction is the increased relative production of ubiquinone as a result of the inhibition of cholesterol demethylation.


Wink and Mitchell, in Chemical Biology of Nitric Oxide: Insights into Regulatory, Cytotoxic, and Cytoprotective Mechanisms of Nitric Oxide, Free Radical Biol. & Med. 25(4): 434-456, Sept. 1998, suggest that changes in NADPH oxidase and nitric oxide levels can affect the availability of iron in a cell. This has catastrophic implications for a selectively affected cancer cell. Id. at 447.

Selective disturbance of metal ion interaction in cancer cells will enhance any probability of apoptosis engineered by other metabolic mechanisms. Particular efficacy for androgen responsive prostate cancer:

The interference with cholesterol synthesis has a further implication for prostate cancer because cholesterol is a precursor to testosterone which has been shown to be an important contributor to prostate cancer. Androgen suppression is a standard therapy for several lines of prostate cancer, but tends to have time limitations before certain cells become androgen insensitive. Prostate Cancer: Biology, Genetics, and the New Therapeutics p. 92 and Ch. 19 at 327-340 (Humana Press, Totowa NJ 2001). While the body has other offsetting mechanisms to continue to signal for generation of androgen, there is at least a partial biochemical effect resulting from interference with cholesterol synthesis.

The invention is not meant to be limited to the disclosures, including best mode of invention herein, and contemplates all equivalents to the invention and similar embodiments to the invention for humans and mammals and veterinary science.
1 Equivalents include all pharmacologically active racemic mixtures, diastereomers and
2 enantiomers of the listed compounds and their pharmacologically acceptable salts.
CLAIMS

We claim:

1. An anti-cancer composition for the purpose of treating at least one cell line of cancer in a mammalian patient comprising:
   in at least one pharmaceutically acceptable carrier, a prophylactically effective amount of a selective COX-2 inhibitor, selected from the group of rofecoxib and celecoxib, to achieve a therapeutically effective change in progression of cancer;
   and a prophylactically effective amount of an HMG-CoA reductase inhibitor selected from the group of statins, including lovastatin, simvastatin and cholestin, to initially achieve a therapeutically effective change in cholesterol, and in combination with said rofecoxib to achieve a therapeutically effective change in progression of cancer.

2. An anti-cancer composition for the purpose of treating at least one cell line of cancer in a mammalian patient comprising:
   in at least one pharmaceutically acceptable carrier, a prophylactically effective amount of a selective COX-2 inhibitor, selected from the group of rofecoxib and celecoxib, to achieve a therapeutically effective change in progression of cancer;
   a prophylactically effective amount of an HMG-CoA reductase inhibitor selected from the group of statins, including lovastatin, simvastatin and cholestin, to initially achieve a therapeutically effective change in cholesterol;
   and a therapeutically effective amount of a glutathione pathway enhancing and detoxifying compound in combination with said selective COX-2 inhibitor and said HMG-CoA reductase inhibitor to achieve a therapeutically effective change in progression of cancer.

3. An anti-cancer composition according to claim 2, further comprising:
   said glutathione pathway enhancing and detoxifying compound being cystine.

4. An anti-cancer composition for the purpose of treating at least one cell line of cancer in a mammalian patient comprising:
   in at least one pharmaceutically acceptable carrier, a prophylactically effective amount of a selective COX-2 inhibitor, selected from the group of rofecoxib and celecoxib, to achieve a therapeutically effective change in progression of cancer;
a prophylactically effective amount an HMG-CoA reductase inhibitor selected from the
group of statins, including lovastatin, simvastatin and cholestin, to initially achieve a
therapeutically effective change in cholesterol;
and in at least one of said at least one carrier, an excipient to augment immune function,
said excipient being characterized by an ability to be a glutathione pathway enhancing
and detoxifying compound, said composition and said prophylactically effective amounts
being combined to achieve a therapeutically effective change in progression of cancer.

5. The anti-cancer composition according to claim 4, further comprising:
said excipient being cystine.

6. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of lovastatin
beginning at 10 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of lovastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 12.5 mg rofecoxib daily, said dose being adjusted upward each six
weeks within the therapeutic window of rofecoxib until at least two inflammatory
response markers show therapeutic change: said at least two inflammatory response
markers including upregulation of IL-12 and downregulation of IL-10; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

7. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of lovastatin
beginning at 10 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of lovastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 12.5 mg rofecoxib daily, said dose being adjusted upward each six
weeks within the therapeutic window of rofecoxib until prophylactically effective
upregulation of isoprostane and lipid peroxidation; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

8. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of simvastatin
beginning at 20 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of simvastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 12.5 mg rofecoxib daily, said dose being adjusted upward each six
weeks within the therapeutic window of rofecoxib until at least two inflammatory
response markers show therapeutic change: said at least two inflammatory response
markers including upregulation of IL-12 and downregulation of IL-10; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

9. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of simvastatin
beginning at 20 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of simvastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 12.5 mg rofecoxib daily, said dose being adjusted upward each six
weeks within the therapeutic window of rofecoxib until prophylactically effective
upregulation of isoprostane and lipid peroxidation; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

10. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of lovastatin
beginning at 10 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of lovastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 100 mg celecoxib daily, said dose being adjusted upward each six weeks
within the therapeutic window of celecoxib until at least two inflammatory response
markers show therapeutic change: said at least two inflammatory response markers
including upregulation of IL-12 and downregulation of IL-10; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

11. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of lovastatin
beginning at 10 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of lovastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 100 mg celecoxib daily, said dose being adjusted upward each six weeks
within the therapeutic window of celecoxib until prophylactically effective upregulation
of isoprostane and lipid peroxidation; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

12. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of simvastatin
beginning at 20 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of simvastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 100 mg celecoxib daily, said dose being adjusted upward each six weeks
within the therapeutic window of celecoxib until at least two inflammatory response
markers show therapeutic change: said at least two inflammatory response markers
including upregulation of IL-12 and downregulation of IL-10; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

13. An anti-cancer composition for the purpose of treating at least one cell line of
cancer in mammalian patient comprising:
in a pharmaceutically acceptable carrier, the combination of a dose of simvastatin
beginning at 20 mg daily adjusted upward each six weeks by 10% within the therapeutic
window of simvastatin until LDL cholesterol has been lowered at least 10%; and
a dose of 100 mg celecoxib daily, said dose being adjusted upward each six weeks
within the therapeutic window of celecoxib until prophylactically effective upregulation
of isoprostane and lipid peroxidation; and
thereafter, until regression of tumor or a decrease in tumor progression, each said
dose being adjusted upward on a six-week basis by at least 10% of the previous dose
being given within the therapeutic window for each respective dose.

14. A method of treating at least one cell line of cancer in a mammalian patient
comprising:
Combining in a pharmaceutically acceptable carrier a prophylactically effective amount
of a selective COX-2 inhibitor, selected from the group of rofecoxib and celecoxib,
within the therapeutic window for said selective COX-2 inhibitor and a prophylactically
effective amount of an HMG-CoA reductase inhibitor selected from the group of statins,
including lovastatin, simvastatin and cholestin, to initially achieve a therapeutically
effective change in cholesterol, and in combination with said selective COX-2 inhibitor
to achieve a therapeutically effective change in progression of cancer.

15. The method according to claim 14, further comprising the step:
incorporating in at least one of said at least one carrier an excipient to augment
immune function, said excipient being characterized by an ability to be glutathione
pathway enhancing and detoxifying compound.

16. The method according to claim 15, further comprising:
Said excipient being cystine.

17. A method of treatment of at least one cell line of cancer in a mammalian patient
comprising:
administering a dose of lovastatin beginning at 10mg in daily amount in a
pharmaceutically acceptable carrier;
administering a dose of rofecoxib beginning at 12.5 mg in daily amount in a
pharmaceutically acceptable carrier,
adjusting said dose of lovastatin upward after six weeks within the therapeutic
window of lovastatin until LDL cholesterol has been lowered at least 10%;
adjusting said dose of rofecoxib upward each six weeks within the therapeutic
window for rofecoxib until at least two inflammatory response markers, tested each six
weeks, show therapeutic change: said at least two inflammatory response markers
including upregulation of IL-12 and downregulation of IL-10; and
thereafter, until regression of tumor or a decrease in tumor progression, adjusting
both doses upward on a six-week basis by at least 10% of the previous dose being given
within the therapeutic window for each of rofecoxib and lovastatin.

18. The method according to claim 17, further comprising:
Combining a therapeutically effective amount of a glutathione pathway enhancing
and detoxifying compound in combination with said rofecoxib and lovastatin to achieve a
therapeutically effective change in progression of cancer.

19. The method according to claim 18, further comprising:
said glutathione pathway and detoxifying compound being cystine.

20. A method of treatment of at least one cell line of cancer in a mammalian patient
comprising:
administering a dose of simvastatin beginning at 20 mg in daily amount in a
pharmaceutically acceptable carrier;
administering a dose of rofecoxib beginning at 12.5 mg in daily amount in a
pharmaceutically acceptable carrier,
adjusting said dose of simvastatin upward after six weeks within the therapeutic
window of simvastatin until LDL cholesterol has been lowered at least 10%;
adjusting said dose of rofecoxib upward each six weeks within the therapeutic
window for rofecoxib until at least two inflammatory response markers, tested each six
weeks, show therapeutic change: said at least two inflammatory response markers
including upregulation of IL-12 and downregulation of IL-10; and
thereafter, until regression of tumor or a decrease in tumor progression, adjusting
both doses upward on a six-week basis by at least 10% of the previous dose being given
within the therapeutic window for each of rofecoxib and simvastatin.

21. The method according to claim 20, further comprising:
Combining a therapeutically effective amount of a glutathione pathway enhancing
and detoxifying compound in combination with said rofecoxib and simvastatin to achieve
a therapeutically effective change in progression of cancer.

22. The method according to claim 21, further comprising:
   said glutathione pathway and detoxifying compound being cystine.

23. A method of treatment of at least one cell line of cancer in a mammalian patient
comprising:
   administering a dose of lovastatin beginning at 10mg in daily amount in a
   pharmaceutically acceptable carrier;
   administering a dose of celecoxib beginning at 100 mg in daily amount in a
   pharmaceutically acceptable carrier,
   adjusting said dose of lovastatin upward after six weeks within the therapeutic
window of lovastatin until LDL cholesterol has been lowered at least 10%;
   adjusting said dose of celecoxib upward each six weeks within the therapeutic
window for celecoxib until at least two inflammatory response markers, tested each six
weeks, show therapeutic change: said at least two inflammatory response markers
including upregulation of IL-12 and downregulation of IL-10; and
   thereafter, until regression of tumor or a decrease in tumor progression, adjusting
both doses upward on a six-week basis by at least 10% of the previous dose being given
within the therapeutic window for each of celecoxib and lovastatin.

24. The method according to claim 23, further comprising:
   Combining a therapeutically effective amount of a glutathione pathway enhancing
and detoxifying compound in combination with said celecoxib and lovastatin to achieve a
therapeutically effective change in progression of cancer.

25. The method according to claim 24, further comprising:
   said glutathione pathway and detoxifying compound being cystine.

26. A method of treatment of at least one cell line of cancer in a mammalian patient
comprising:
   administering a dose of simvastatin beginning at 20 mg in daily amount in a
   pharmaceutically acceptable carrier;
   administering a dose celecoxib beginning at 100 mg in daily amount in a
   pharmaceutically acceptable carrier,
   adjusting said dose of simvastatin upward after six weeks within the therapeutic
window of simvastatin until LDL cholesterol has been lowered at least 10%;

adjusting said dose of celecoxib upward each six weeks within the therapeutic
window for celecoxib until at least two inflammatory response markers, tested each six
weeks, show therapeutic change: said at least two inflammatory response markers
including upregulation of IL-12 and downregulation of IL-10; and

thereafter, until regression of tumor or a decrease in tumor progression, adjusting
both doses upward on a six-week basis by at least 10% of the previous dose being given
within the therapeutic window for each of celecoxib and simvastatin.

27. The method according to claim 26, further comprising:

Combining a therapeutically effective amount of a glutathione pathway enhancing
and detoxifying compound in combination with said celecoxib and simvastatin to achieve
a therapeutically effective change in progression of cancer.

28. The method according to claim 27, further comprising:

said glutathione pathway and detoxifying compound being cystine.

29. A method of treating at least one cell line of cancer in a mammalian patient
comprising:

combining in a pharmaceutically acceptable carrier a prophylactically effective
amount of rofecoxib within the therapeutic window for rofecoxib, and a
prophylactically effective amount of lovastatin within the therapeutic window for
lovastatin to initially achieve a therapeutically effective change in cholesterol, and
a therapeutically effective amount of a glutathione pathway enhancing and
detoxifying compound in combination with said rofecoxib and lovastatin to
achieve a therapeutically effective change in progression of cancer.

30. The method according to claim 29, further comprising:

said glutathione pathway and detoxifying compound being cystine.

31. A method of treatment of at least one cell line of cancer in a mammalian patient
comprising:

Administering a dose of lovastatin beginning at 10mg in daily amount in a
pharmaceutically acceptable carrier;

Administering a dose rofecoxib beginning at 12.5 mg in daily amount in a
pharmaceutically acceptable carrier,
Adjusting said dose of lovastatin upward after six weeks within the therapeutic window of lovastatin until LDL cholesterol has been lowered at least 10%;

Adjusting said dose of rofecoxib upward each six weeks until prophylactically effective upregulation of isoprostane and lipid peroxidation; and

thereafter, until regression of tumor or a decrease in tumor progression, adjusting both doses upward on a six-week basis by at least 10% of the previous dose being given within the therapeutic window for each of rofecoxib and lovastatin.

32. The method according to claim 31, further comprising:

Combining a therapeutically effective amount of a glutathione pathway enhancing and detoxifying compound in combination with said rofecoxib and lovastatin to achieve a therapeutically effective change in progression of cancer.

33. The method according to claim 32, further comprising:

said glutathione pathway and detoxifying compound being cystine.

34. A method of treatment of at least one cell line of cancer in a mammalian patient comprising:

Administering a dose of simvastatin beginning at 20 mg in daily amount in a pharmaceutically acceptable carrier;

Administering a dose rofecoxib beginning at 12.5 mg in daily amount in a pharmaceutically acceptable carrier,

Adjusting said dose of simvastatin upward after six weeks within the therapeutic window of simvastatin until LDL cholesterol has been lowered at least 10%;

Adjusting said dose of rofecoxib upward each six weeks until prophylactically effective upregulation of isoprostane and lipid peroxidation; and

thereafter, until regression of tumor or a decrease in tumor progression, adjusting both doses upward on a six-week basis by at least 10% of the previous dose being given within the therapeutic window for each of rofecoxib and simvastatin.

35. The method according to claim 34, further comprising:

Combining a therapeutically effective amount of a glutathione pathway enhancing and detoxifying compound in combination with said rofecoxib and simvastatin to achieve a therapeutically effective change in progression of cancer.

36. The method according to claim 35, further comprising:
said glutathione pathway and detoxifying compound being cystine.

37. A method of treatment of at least one cell line of cancer in a mammalian patient comprising:
   Administering a dose of lovastatin beginning at 10mg in daily amount in a
   pharmaceutically acceptable carrier;
   Administering a dose celecoxib beginning at 100 mg in daily amount in a
   pharmaceutically acceptable carrier,
   Adjusting said dose of lovastatin upward after six weeks within the therapeutic
   window of lovastatin until LDL cholesterol has been lowered at least 10%;
   Adjusting said dose of celecoxib upward each six weeks until prophylactically
   effective upregulation of isoprostane and lipid peroxidation; and
   thereafter, until regression of tumor or a decrease in tumor progression, adjusting
   both doses upward on a six-week basis by at least 10% of the previous dose being given
   within the therapeutic window for each of celecoxib and lovastatin.

38. The method according to claim 37, further comprising:
   Combining a therapeutically effective amount of a glutathione pathway enhancing
   and detoxifying compound in combination with said celecoxib and lovastatin to achieve a
   therapeutically effective change in progression of cancer.

39. The method according to claim 38, further comprising:
   said glutathione pathway and detoxifying compound being cystine.

40. A method of treatment of at least one cell line of cancer in a mammalian patient
comprising:
   Administering a dose of simvastatin beginning at 20 mg in daily amount in a
   pharmaceutically acceptable carrier;
   Administering a dose celecoxib beginning at 100 mg in daily amount in a
   pharmaceutically acceptable carrier,
   Adjusting said dose of simvastatin upward after six weeks within the therapeutic
   window of simvastatin until LDL cholesterol has been lowered at least 10%;
   Adjusting said dose of celecoxib upward each six weeks until prophylactically
   effective upregulation of isoprostane and lipid peroxidation; and
   thereafter, until regression of tumor or a decrease in tumor progression, adjusting
both doses upward on a six-week basis by at least 10% of the previous dose being given
within the therapeutic window for each of celecoxib and simvastatin.
41. The method according to claim 40, further comprising:
   Combining a therapeutically effective amount of a glutathione pathway enhancing
   and detoxifying compound in combination with said celecoxib and simvastatin to achieve
   a therapeutically effective change in progression of cancer.
42. The method according to claim 41, further comprising:
   said glutathione pathway and detoxifying compound being cystine.
43. A method of manufacturing an anti-cancer combination comprising the following
   steps:
   incorporating in at least one pharmaceutically carrier at least the lowest dose in the
   therapeutic window of an HMG-CoA reductase inhibitor, selected from the group of
   statins, including lovastatin, simvastatin, and cholestain; and
   incorporating in at least one pharmaceutically acceptable carrier at least the lowest dose
   in the therapeutic window of a selective COX-2 inhibitor, selected from the group of
   rofecoxib and celecoxib.
44. A method of manufacturing an anti-cancer combination comprising the following
   steps:
   incorporating in at least one pharmaceutically carrier at least the lowest dose in the
   therapeutic window of an HMG-CoA reductase inhibitor, selected from the group of
   statins, including lovastatin, simvastatin, and cholestain; and
   incorporating in at least one pharmaceutically acceptable carrier at least the lowest dose
   in the therapeutic window of a selective COX-2 inhibitor, selected from the group of
   rofecoxib and celecoxib; and
   incorporating in at least one of said at least one carrier an excipient to augment
   immune function, said excipient being characterized by an ability to be glutathione
   pathway enhancing and detoxifying compound.
45. The method according to claim 44, further comprising:
   said excipient being cystine.